Core Viewpoint - The company, Boten Co., Ltd. (300363.SZ), plans to acquire a portion of shares in Shenzhen Yifeng Yunding Venture Capital Partnership (Limited Partnership) for a nominal price of 1 yuan, which will involve a capital contribution obligation of 20 million yuan as per the partnership agreement [1] Group 1: Investment Details - The acquisition will allow the company to indirectly invest in Hangzhou Yifeng Runjun Venture Capital Partnership (Limited Partnership) through the Yifeng Yunding Fund [1] - The Yifeng Yunding Fund specializes in investments in the healthcare sector, focusing on innovative drugs, high-end medical devices, and biotechnology [1] Group 2: Strategic Implications - This investment is expected to leverage the resources of a professional investment institution, aiding the company in business development and strategic resource acquisition [1] - The projects funded by the Yifeng Runjun Fund may present opportunities for business collaboration and synergies with the company [1]

智通财经APP讯，博腾股份(300363.SZ)发布公告，公司拟以1元对价受让陈彦希持有的深圳市倚锋云鼎 创业投资合伙企业(有限合伙)(简称"倚锋云鼎基金")部分份额，受让完成后，公司将按照《合伙协议》 的约定履行2000万元认缴份额的实缴出资义务。倚锋云鼎基金专项投资于杭州倚锋润君创业投资合伙企 业(有限合伙)(简称"倚锋润君基金")，公司将通过投资倚锋云鼎基金，实现对倚锋润君基金的间接投 资。 深圳市倚锋投资管理企业(有限合伙)是国内最早一批生物医药专业投资机构，专注于全球生物医药投 资。本次投资有助于公司借助专业投资机构的优质资源，帮助公司业务和客户导入及战略资源引入。倚 锋云鼎基金专项投资于倚锋润君基金，倚锋润君基金主要投资于医疗健康板块的原创新药、高端医疗器 械、生物科技及国内外相关领域的优质标的企业，所投资项目可能与公司存在业务合作等协同关系。 ...